Cao Zhisong, Mendoza John, Dejesus Albert, Vardeman Dana, Giovanella Beppino
The Christus Stehlin Foundation for Cancer Research, Houston, TX 77003, USA.
Int J Mol Med. 2008 Apr;21(4):477-87.
Twenty-eight new aromatic esters of camptothecins 2-29 were prepared in yields of 5 to 96% by straight acylation of camptothecin (1a) and 9-nitrocamptothecin (1b) with various aromatic acids as acylating agents. All of these esters were tested against 14 different human cancer cell lines. The antitumor activity of these compounds was related to the nature of the substituting groups of their side aromatic chains. In general, esters with strong electron-withdrawing groups on their side aromatic chains were active; esters with halogen-substituted side aromatic chains were slightly active; and esters without any substituting groups on their side aromatic chains were practically inactive. The IC50 studies showed that the majority of these esters were not as potent as their parental compounds 1a and 1b; whereas, the potencies of esters 6 and 25 were exceptionally high, much higher than the commercial camptothecin analogues and comparable to (or slightly more potent than) their parental compounds.
以喜树碱(1a)和9-硝基喜树碱(1b)为原料,用各种芳香酸作为酰化剂进行直接酰化反应,制备了28种新的喜树碱2 - 29芳香酯,产率为5%至96%。所有这些酯都针对14种不同的人类癌细胞系进行了测试。这些化合物的抗肿瘤活性与其侧链芳香链取代基的性质有关。一般来说,侧链芳香链上带有强吸电子基团的酯具有活性;侧链芳香链被卤素取代的酯活性稍低;而侧链芳香链上没有任何取代基的酯实际上没有活性。IC50研究表明,这些酯中的大多数不如其母体化合物1a和1b有效;然而,酯6和25的效力异常高,远高于市售喜树碱类似物,与它们的母体化合物相当(或稍强)。